On 22 December 2015 the Philippines became the first Asian country to approve the sale of the world’s 1st-ever dengue vaccine, Dengvaxia.
The Philippines’ Food & Drug Administration approved the dengue vaccine for the prevention of disease caused by all 4 dengue types in individuals from 9 to 45 years old living in endemic areas.
Earlier on 9th December 2015, Dengvaxia, manufactured by the French pharmaceutical giant Sanofi, secured its 1st regulatory approval in Mexico.
Key facts related to Dengvaxia vaccine
• The Federal Commission for the Protection against Sanitary Risks (COFEPRIS) approved Dengvaxia for the prevention of disease caused by all 4 dengue virus serotypes in preadolescents, adolescents & adults, 9 to 45 years of age living in endemic areas.
• The COFEPRIS approval of Dengvaxia is based on results from an extensive clinical development program involving over 40000 people of different ages, geographic or epidemiological settings, and ethnic and socio-economic backgrounds living in 15 countries.
• According to a World Health Orgnisation report published in late 2014, the vaccine had an average rate of effectiveness of about 60.8 % in protecting against the 4 strains of dengue now circulating.
About Sanofi
• Sanofi is a French multinational pharmaceutical company headquartered in Paris, France.
• It was founded in 1973 as subsidiary of Elf Aquitaine.
• The company engages in the research & development(R&D), manufacturing and marketing of pharmaceutical drugs principally in the prescription market.
Philippines became 1st Asian country to approve world"s 1st-ever dengue vaccine
No comments:
Post a Comment